8-K: Cyclo Therapeutics Secures $2 Million in Convertible Debt Financing from Rafael Holdings

Cyclo Therapeutics has entered into an amended agreement with Rafael Holdings, issuing a $2 million convertible promissory note to bolster working capital.

Summary

• Cyclo Therapeutics has secured a $2 million convertible promissory note from Rafael Holdings.
• This note amends and restates a previous agreement from June 11, 2024, which also involved a $2 million note.
• The new note matures on November 11, 2024, and carries a 5% annual interest rate, payable at maturity.
• The company can prepay the note at any time.
• Rafael Holdings, which owns approximately 31.5% of Cyclo Therapeutics' common stock, has the option to convert the note into common stock.
• Conversion is automatic if Cyclo Therapeutics secures a qualified financing of at least $8 million.
• The proceeds from the note will be used for working capital and general corporate purposes.
• An event of default, such as failure to pay principal or interest on either note, could lead to acceleration of obligations.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is taking on debt, it is securing necessary funding from a major shareholder. The conversion feature is a positive, but the short maturity and default interest rate are potential concerns.

Positives

• The $2 million in funding provides Cyclo Therapeutics with additional working capital.
• The ability to prepay the note offers financial flexibility.
• The conversion feature could lead to a reduction in debt if the company secures a qualified financing.
• The funding comes from a major existing shareholder, indicating confidence in the company.

Negatives

• The company is taking on additional debt, which increases its financial obligations.
• Failure to meet payment obligations could trigger an event of default and increase the interest rate to 12%.
• The conversion of the note could dilute existing shareholders if Rafael Holdings chooses to convert.
• The note matures in a relatively short timeframe, requiring repayment or conversion by November 11, 2024.

Risks

• The company's ability to repay the note or secure a qualified financing by the maturity date is uncertain.
• Failure to meet the terms of the note could lead to an event of default and acceleration of obligations.
• The conversion of the note could dilute existing shareholders.
• The company's reliance on debt financing may indicate challenges in generating sufficient cash flow from operations.

Future Outlook

The company intends to use the proceeds for working capital and general corporate purposes. The note may convert to equity upon a qualified financing or sale transaction.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

This financing is a common method for biotech companies to raise capital, especially those in the development stage. The use of convertible notes allows for flexibility and potential conversion to equity, which can be attractive to investors.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small to mid-sized biotech companies, similar to companies like Athersys and Ocugen, which have also used convertible debt to fund operations.
• The 5% interest rate is relatively standard for this type of financing, although the default rate of 12% is a significant increase.
• The conversion terms, based on a qualified financing or sale transaction, are typical for convertible notes in the biotech sector.
• The maturity date of November 11, 2024, is a relatively short term, which is not uncommon for bridge financing.

Related Party Transactions

• The convertible promissory note was issued to Rafael Holdings, a major shareholder of Cyclo Therapeutics, making this a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted to equity.
• Creditors are impacted by the new debt obligation.
• Employees may benefit from the increased working capital, which could support operations and job security.

Next Steps

• The company will use the funds for working capital and general corporate purposes.
• The company will need to either repay the note by November 11, 2024, or secure a qualified financing or sale transaction to trigger conversion.
• The company will need to monitor its financial performance to avoid an event of default.

Key Dates

Keywords

convertible note, financing, debt, Rafael Holdings, working capital, promissory note, conversion, qualified financing, common stock, Cyclo Therapeutics